Почетна › Alopecija areata › Indijana
Kliničke studije za Alopecija areata u državi Indijana
7 studija za Alopecija areata traži učesnike na lokacijama u državi Indijana.
Gradovi u državi Indijana
Zvanični tekst studije (na engleskom)
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
- Dawes Fretzin- Indianapolis /ID# 283498, Indianapolis
Тражи се учесникФаза 3
Узраст од 6 до 17 · Оба пола · Ажурирано 27. 10. 2026. · NCT07772492A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07733765A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06873945A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- Indiana University Health University Hospital /ID# 259827, Indianapolis
Тражи се учесникФаза 3
Узраст од 12 до 63 · Оба пола · Ажурирано 19. 10. 2026. · NCT06012240A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Тражи се учесникФаза 3
Узраст од 6 до 14 · Оба пола · Ажурирано 15. 10. 2026. · NCT07029828HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
- Dawes Fretzin Clinical Research Group, Indianapolis
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 15. 9. 2026. · NCT07049328Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- Ds Research - Indiana, Clarksville
- Dawes Fretzin Clinical Research Group Llc., Indianapolis
Тражи се учесникФаза 3
Узраст од 12 до 17 · Оба пола · Ажурирано 28. 1. 2026. · NCT07133308Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.